
.png)
We welcome potential partners to learn more about our new companies featuring next-generation medical products.
Cleveland Clinic Innovations' goal is to support venture-stage companies in their efforts to commercialize Cleveland Clinic intellectual property and positively impact patient care.
Companies Currently Fundraising
- Turning visitors into leads.

.jpeg?width=500&height=334&name=Abcon_New-Cancer-Treatment-Being-Developed-for-Incurable-Lymphoma%20(1).jpeg)
Abcon Therapeutics
Field: T-cell mediated diseases and related cancers, with initial focus on T-Cell Lymphoma (TCL).
Mode and MOA: First product, ATX101, is a fully humanized monoclonal antibody-drug conjugate (ADC) that targets CD6, an established T-Cell specific receptor.
Data: ATX101 has been highly effective in treating preclinical models of TCL, demonstrating tumor shrinkage and inhibition of tumor metastasis.
Current development status: IND-enabling tox studies.
IP: Exclusive license to Cleveland Clinic-developed mAbs and ADCs; Issued and pending patent applications covering composition of matter and methods of treating T-cell mediated disease.
Raise: Active Series A Round.


Mobius Care
- Field: Inflammatory bowel disease (IBD).
Mode and MOA: Novel AI digital pathology tool for stratification of IBD patients to existing drugs and candidates under development.
Data: In vitro and in vivo proof of concept established.
Current development status: In vivo validation.
IP: Exclusive option to Cleveland Clinic - and Washington University-developed intellectual property; Pending patent applications covering diagnostic methodologies.- Raise: Active Seed Round.

.jpg?width=500&height=396&name=f2ff6e_47848a981e684d5f9f57af0b6743f01e~mv2%20(1).jpg)
Neurotherapia
Field: Neuroinflammation for CNS disease; initially targeting Alzheimer’s Disease (AD).
Mode and MOA: Small molecule therapies targeting microglial cells; Lead compound NTRX-07 is a CB2 agonist shown to reduce neuroinflammation.
Data: Phase 1 safety studies in AD completed successfully.
Current development status: Ready for phase 2 clinical studies.
IP: Exclusive license to Cleveland Clinic -developed small molecules; Issued and pending patent applications covering composition and method of use for treating neuroinflammation.
Raise: Active Series B Round.
- Turning visitors into leads.


Zehna Therapeutics
Field: Cardiometabolic diseases with initial focus on cardiovascular disease (CVD) and chronic kidney disease (CKD).
Mode and MOA: Small molecules inhibit gut microbial enzyme CutC, preventing molecular conversion to trimethylamine N-oxide (TMAO) – a metabolite connected to CVD and CKD risk.
Data: In vivo proof-of-concept established.
Current development status: Expect IND-ready in 2024.
IP: Excusive license to Cleveland Clinic -developed small molecules; Issued and pending patent applications covering compositions and methods of use.
Raise: Active Series A Round.
Co-Creation Opportunities
PSMA
Field: Radiotheranostics for treatment of prostate cancer.
Mode and MOA: Next-generation PSMA-targeting radioligand has higher specificity than on-market prostate cancer radiotherapies, reducing side effects.
Data: In vivo proof-of-concept established.
Current development status: GMP manufacturing completed and released under CoA; IND-enabling stability and acute toxicity studies in progress; Phase 0 study ready expected 2024.
IP: Excusive option to Cleveland Clinic -developed compounds; Issued and pending patent applications covering compositions and methods of use.
Ask: Seeking co-investment or co-development partners.

ComAb
Field: Complement-mediated diseases.
Mode and MOA: Pipeline of monoclonal antibody (mAb) therapeutics targeting various aspects of the complement cascade; lead programs targeting C6, a key protein in membrane attack complex (MAC) formation.
Data: In vivo proof-of-concept established.
Current development status: Lead program fully humanized and entering IND-enabling studies.
IP: Cleveland Clinic has filed patent applications covering compositions and methods of use.
Ask: Seeking co-investment or co-development partners.
.png?width=800&height=800&name=prostate%20(1).png)


